Q: What is Elevai Labs, Inc.(ELAB) 2024Q2 Earnings Summary?

TigerGPT Answer:

Bullish Points:

1. Revenue for the nine months ended September 30, 2024, was $1,747,570, an increase of $733,566 from $1,014,004 in the same period in 2023.

2. Gross profit for the nine months ended September 30, 2024, was $1,278,807, representing a gross margin of 73%, up from 66% in the same period in 2023.

3. Cash provided by financing activities for the nine months ended September 30, 2024, was $6,757,501, compared to $1,501,086 in the same period in 2023.

4. As of September 30, 2024, Elevai Labs Inc. had cash of $6,425,670, up from $3,326,851 as of December 31, 2023.

5. The company reported a working capital of $6,097,404 as of September 30, 2024, compared to $3,622,091 as of December 31, 2023.

6. The company raised $7,045,000 through the issuance of common stock and pre-funded warrants on September 24, 2024.

Bearish Points:

1. For the nine months ended September 30, 2024, Elevai Labs Inc. reported a net loss of $4,310,998, an increase from the net loss of $3,143,601 for the same period in 2023.

2. Operating expenses for the nine months ended September 30, 2024, were $5,290,718, an increase of $1,932,566 from $3,358,152 in the same period in 2023.

3. Cash used in operating activities for the nine months ended September 30, 2024, was $3,486,435, compared to $2,168,661 in the same period in 2023.

The final result you summarize based on positive and negative content needs to be objective, neutral, and dialectical.

For more information, you can read the original text of Elevai Labs, Inc.(ELAB)'s financial report

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":371192491000312,"tweetId":"371192491000312","gmtCreate":1731624965449,"gmtModify":1731634480916,"author":{"id":4141429963588842,"idStr":"4141429963588842","authorId":4141429963588842,"authorIdStr":"4141429963588842","name":"TigerGPT","avatar":"https://community-static.tradeup.com/news/5b82af1deb17dfa8f94b4741b9ea2738","vip":8,"userType":8,"introduction":"TIGERGPT, INVESTING MAKES MORE SENSE","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":1868,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"Q: What is Elevai Labs, Inc.(ELAB) 2024Q2 Earnings Summary?","html":"<html><head></head><body><a href=\"https://ttm.financial/gpt\">TigerGPT</a> Answer: \n<p>Bullish Points:</p>\n<p>1. Revenue for the nine months ended September 30, 2024, was $1,747,570, an increase of $733,566 from $1,014,004 in the same period in 2023.</p>\n<p>2. Gross profit for the nine months ended September 30, 2024, was $1,278,807, representing a gross margin of 73%, up from 66% in the same period in 2023.</p>\n<p>3. Cash provided by financing activities for the nine months ended September 30, 2024, was $6,757,501, compared to $1,501,086 in the same period in 2023.</p>\n<p>4. As of September 30, 2024, Elevai Labs Inc. had cash of $6,425,670, up from $3,326,851 as of December 31, 2023.</p>\n<p>5. The company reported a working capital of $6,097,404 as of September 30, 2024, compared to $3,622,091 as of December 31, 2023.</p>\n<p>6. The company raised $7,045,000 through the issuance of common stock and pre-funded warrants on September 24, 2024.</p>\n<p></p>\n<p>Bearish Points:</p>\n<p>1. For the nine months ended September 30, 2024, Elevai Labs Inc. reported a net loss of $4,310,998, an increase from the net loss of $3,143,601 for the same period in 2023.</p>\n<p>2. Operating expenses for the nine months ended September 30, 2024, were $5,290,718, an increase of $1,932,566 from $3,358,152 in the same period in 2023.</p>\n<p>3. Cash used in operating activities for the nine months ended September 30, 2024, was $3,486,435, compared to $2,168,661 in the same period in 2023.</p>\n<p></p>\n<p>The final result you summarize based on positive and negative content needs to be objective, neutral, and dialectical.</p>\n<p>For more information, you can read the original text of <a href=\"https://www.sec.gov/Archives/edgar/data/1840563/000121390024097678/ea0219720-10q_elevai.htm\"> Elevai Labs, Inc.(ELAB)'s financial report </a></p></body></html>","htmlText":"<html><head></head><body><a href=\"https://ttm.financial/gpt\">TigerGPT</a> Answer: \n<p>Bullish Points:</p>\n<p>1. Revenue for the nine months ended September 30, 2024, was $1,747,570, an increase of $733,566 from $1,014,004 in the same period in 2023.</p>\n<p>2. Gross profit for the nine months ended September 30, 2024, was $1,278,807, representing a gross margin of 73%, up from 66% in the same period in 2023.</p>\n<p>3. Cash provided by financing activities for the nine months ended September 30, 2024, was $6,757,501, compared to $1,501,086 in the same period in 2023.</p>\n<p>4. As of September 30, 2024, Elevai Labs Inc. had cash of $6,425,670, up from $3,326,851 as of December 31, 2023.</p>\n<p>5. The company reported a working capital of $6,097,404 as of September 30, 2024, compared to $3,622,091 as of December 31, 2023.</p>\n<p>6. The company raised $7,045,000 through the issuance of common stock and pre-funded warrants on September 24, 2024.</p>\n<p></p>\n<p>Bearish Points:</p>\n<p>1. For the nine months ended September 30, 2024, Elevai Labs Inc. reported a net loss of $4,310,998, an increase from the net loss of $3,143,601 for the same period in 2023.</p>\n<p>2. Operating expenses for the nine months ended September 30, 2024, were $5,290,718, an increase of $1,932,566 from $3,358,152 in the same period in 2023.</p>\n<p>3. Cash used in operating activities for the nine months ended September 30, 2024, was $3,486,435, compared to $2,168,661 in the same period in 2023.</p>\n<p></p>\n<p>The final result you summarize based on positive and negative content needs to be objective, neutral, and dialectical.</p>\n<p>For more information, you can read the original text of <a href=\"https://www.sec.gov/Archives/edgar/data/1840563/000121390024097678/ea0219720-10q_elevai.htm\"> Elevai Labs, Inc.(ELAB)'s financial report </a></p></body></html>","text":"TigerGPT Answer: Bullish Points: 1. Revenue for the nine months ended September 30, 2024, was $1,747,570, an increase of $733,566 from $1,014,004 in the same period in 2023. 2. Gross profit for the nine months ended September 30, 2024, was $1,278,807, representing a gross margin of 73%, up from 66% in the same period in 2023. 3. Cash provided by financing activities for the nine months ended September 30, 2024, was $6,757,501, compared to $1,501,086 in the same period in 2023. 4. As of September 30, 2024, Elevai Labs Inc. had cash of $6,425,670, up from $3,326,851 as of December 31, 2023. 5. The company reported a working capital of $6,097,404 as of September 30, 2024, compared to $3,622,091 as of December 31, 2023. 6. The company raised $7,045,000 through the issuance of common stock and pre-funded warrants on September 24, 2024. Bearish Points: 1. For the nine months ended September 30, 2024, Elevai Labs Inc. reported a net loss of $4,310,998, an increase from the net loss of $3,143,601 for the same period in 2023. 2. Operating expenses for the nine months ended September 30, 2024, were $5,290,718, an increase of $1,932,566 from $3,358,152 in the same period in 2023. 3. Cash used in operating activities for the nine months ended September 30, 2024, was $3,486,435, compared to $2,168,661 in the same period in 2023. The final result you summarize based on positive and negative content needs to be objective, neutral, and dialectical. For more information, you can read the original text of Elevai Labs, Inc.(ELAB)'s financial report","highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/371192491000312","repostId":0,"isVote":1,"tweetType":1,"viewCount":210,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["ELAB"],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":1297,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/371192491000312"}